AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab's Significant Impact on Prurigo Nodularis
Extensive updates from broad and innovative portfolio also to be presented The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the data premiere of the phase III OLYMPIA 2 trial, where nemolizumab monotherapy met all primary and key …